Previous 10 | Next 10 |
Summary Reata Pharmaceuticals has an FDA decision (PDUFA) date of February 28 for omaveloxolone. Bardoxolone is in three Phase 3 trials for different types of polycystic kidney disease. The platform and pipeline promise significant revenue by 2030. Reata Pharmaceuticals ( ...
Reata Pharmaceuticals, Inc . (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Conference on Novem...
Reata Pharmaceuticals, Inc. (RETA) Q3 2022 Results Conference Call November 08, 2022 08:30 AM ET Company Participants Warren Huff - Chief Executive Officer Manmeet Soni - President Colin Meyer - Chief Innovation Officer Seemi Khan - Chief Medical Officer ...
Reata Pharmaceuticals ( NASDAQ: RETA ) stock rose ~15% on Tuesday after the company said in its Q3 results that it plans to submit an application to the European Medicines Agency (EMA) this year for omaveloxolone to treat Friedreich's Ataxia. In additi...
Shares of Reata Pharmaceuticals (NASDAQ: RETA) had soared 11.8% higher as of 11 a.m. ET on Tuesday. The big gain came after the drugmaker provided its third-quarter update prior to the opening of trading. Reata reported Q3 collaboration revenue of $540,000 and a net loss of $79 ...
NDA for Omaveloxolone for Patients With Friedreich’s Ataxia Under Review With PDUFA Date of February 28, 2023 FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the Omaveloxolone NDA and the Late Cycle Meeting Has Been Completed Provides Update on Commercial...
NDA for Omaveloxolone for Patients With Friedreich’s Ataxia Under Review With PDUFA Date of February 28, 2023 FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the Omaveloxolone NDA and the Late Cycle Meeting Has Been Completed Provide...
Reata Pharmaceuticals ( NASDAQ: RETA ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is -$2.05 (-61.4% Y/Y) and the consensus Revenue Estimate is $0.73M (-90.1% Y/Y). Over the last 2 years, RETA ...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter en...
Clinical-stage biopharmaceutical companies Karuna Therapeutics (NASDAQ: KRTX) and Reata Pharmaceuticals (NASDAQ: RETA) are up more than 64% and 17% so far this year thanks to potential blockbuster drugs. Karuna's lead candidate, KarXT, has excited investors becau...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...